List of Tables
Table 1. Global Checkpoint Inhibitors for Treating Cancer Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Checkpoint Inhibitors for Treating Cancer Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Checkpoint Inhibitors for Treating Cancer Market Competitive Situation by Manufacturers in 2025
Table 4. Global Checkpoint Inhibitors for Treating Cancer Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Checkpoint Inhibitors for Treating Cancer Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Checkpoint Inhibitors for Treating Cancer Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Checkpoint Inhibitors for Treating Cancer Average Price (USD/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Checkpoint Inhibitors for Treating Cancer, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Checkpoint Inhibitors for Treating Cancer, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Checkpoint Inhibitors for Treating Cancer, Product Types and Applications
Table 12. Global Key Manufacturers of Checkpoint Inhibitors for Treating Cancer, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Checkpoint Inhibitors for Treating Cancer Companies by Tier (Tier 1, Tier 2, Tier 3), based on Checkpoint Inhibitors for Treating Cancer Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Checkpoint Inhibitors for Treating Cancer Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Checkpoint Inhibitors for Treating Cancer Sales by Region (K Units), 2021–2026
Table 18. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region (2021–2026)
Table 19. Global Checkpoint Inhibitors for Treating Cancer Sales by Region (K Units), 2027–2032
Table 20. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region (2027–2032)
Table 21. Global Checkpoint Inhibitors for Treating Cancer Revenue by Region (US$ Million), 2021–2026
Table 22. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region (2021–2026)
Table 23. Global Checkpoint Inhibitors for Treating Cancer Revenue by Region (US$ Million), 2027–2032
Table 24. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region (2027–2032)
Table 25. North America Checkpoint Inhibitors for Treating Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Checkpoint Inhibitors for Treating Cancer Sales by Country (K Units), 2021–2026
Table 27. North America Checkpoint Inhibitors for Treating Cancer Sales by Country (K Units), 2027–2032
Table 28. North America Checkpoint Inhibitors for Treating Cancer Revenue by Country (US$ Million), 2021–2026
Table 29. North America Checkpoint Inhibitors for Treating Cancer Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Checkpoint Inhibitors for Treating Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Checkpoint Inhibitors for Treating Cancer Sales by Country (K Units), 2021–2026
Table 32. Europe Checkpoint Inhibitors for Treating Cancer Sales by Country (K Units), 2027–2032
Table 33. Europe Checkpoint Inhibitors for Treating Cancer Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Checkpoint Inhibitors for Treating Cancer Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Checkpoint Inhibitors for Treating Cancer Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Checkpoint Inhibitors for Treating Cancer Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Checkpoint Inhibitors for Treating Cancer Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Checkpoint Inhibitors for Treating Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Checkpoint Inhibitors for Treating Cancer Sales by Country (K Units), 2021–2026
Table 42. Latin America Checkpoint Inhibitors for Treating Cancer Sales by Country (K Units), 2027–2032
Table 43. Latin America Checkpoint Inhibitors for Treating Cancer Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Checkpoint Inhibitors for Treating Cancer Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue by Country (US$ Million), 2027–2032
Table 50. Global Checkpoint Inhibitors for Treating Cancer Sales (K Units) by Type (2021–2026)
Table 51. Global Checkpoint Inhibitors for Treating Cancer Sales (K Units) by Type (2027–2032)
Table 52. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2021–2026)
Table 53. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2027–2032)
Table 54. Global Checkpoint Inhibitors for Treating Cancer Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Checkpoint Inhibitors for Treating Cancer Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Type (2021–2026)
Table 57. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Type (2027–2032)
Table 58. Global Checkpoint Inhibitors for Treating Cancer Price (USD/Unit) by Type (2021–2026)
Table 59. Global Checkpoint Inhibitors for Treating Cancer Price (USD/Unit) by Type (2027–2032)
Table 60. Global Checkpoint Inhibitors for Treating Cancer Sales (K Units) by Application (2021–2026)
Table 61. Global Checkpoint Inhibitors for Treating Cancer Sales (K Units) by Application (2027–2032)
Table 62. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2021–2026)
Table 63. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2027–2032)
Table 64. Global Checkpoint Inhibitors for Treating Cancer Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Checkpoint Inhibitors for Treating Cancer Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application (2021–2026)
Table 67. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application (2027–2032)
Table 68. Global Checkpoint Inhibitors for Treating Cancer Price (USD/Unit) by Application (2021–2026)
Table 69. Global Checkpoint Inhibitors for Treating Cancer Price (USD/Unit) by Application (2027–2032)
Table 70. Bristol-Myers Squibb(BMS) Company Information
Table 71. Bristol-Myers Squibb(BMS) Description and Business Overview
Table 72. Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 73. Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Product
Table 74. Bristol-Myers Squibb(BMS) Recent Developments/Updates
Table 75. Merck Company Information
Table 76. Merck Description and Business Overview
Table 77. Merck Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 78. Merck Checkpoint Inhibitors for Treating Cancer Product
Table 79. Merck Recent Developments/Updates
Table 80. Roche Company Information
Table 81. Roche Description and Business Overview
Table 82. Roche Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 83. Roche Checkpoint Inhibitors for Treating Cancer Product
Table 84. Roche Recent Developments/Updates
Table 85. Key Raw Materials Lists
Table 86. Raw Materials Key Suppliers Lists
Table 87. Checkpoint Inhibitors for Treating Cancer Distributors List
Table 88. Checkpoint Inhibitors for Treating Cancer Customers List
Table 89. Checkpoint Inhibitors for Treating Cancer Market Trends
Table 90. Checkpoint Inhibitors for Treating Cancer Market Drivers
Table 91. Checkpoint Inhibitors for Treating Cancer Market Challenges
Table 92. Checkpoint Inhibitors for Treating Cancer Market Restraints
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
Table 96. Authors List of This Report
List of Figures
Figure 1. Product Picture of Checkpoint Inhibitors for Treating Cancer
Figure 2. Global Checkpoint Inhibitors for Treating Cancer Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Checkpoint Inhibitors for Treating Cancer Market Share by Type: 2025 & 2032
Figure 4. PD-1 Inhibitors Product Picture
Figure 5. PD-L1 Inhibitors Product Picture
Figure 6. CTLA-4 Inhibitors Product Picture
Figure 7. Global Checkpoint Inhibitors for Treating Cancer Market Value by Application (US$ Million), 2021–2032
Figure 8. Global Checkpoint Inhibitors for Treating Cancer Market Share by Application: 2025 & 2032
Figure 9. Melanoma Treatment
Figure 10. Bladder Cancer Treatment
Figure 11. Other
Figure 12. Global Checkpoint Inhibitors for Treating Cancer Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 13. Global Checkpoint Inhibitors for Treating Cancer Market Size (US$ Million), 2021–2032
Figure 14. Global Checkpoint Inhibitors for Treating Cancer Sales (K Units), 2021–2032
Figure 15. Global Checkpoint Inhibitors for Treating Cancer Average Price (USD/Unit), 2021–2032
Figure 16. Checkpoint Inhibitors for Treating Cancer Report Years Considered
Figure 17. Checkpoint Inhibitors for Treating Cancer Sales Share by Manufacturers in 2025
Figure 18. Global Checkpoint Inhibitors for Treating Cancer Revenue Share by Manufacturers in 2025
Figure 19. Top 5 and Top 10 Global Checkpoint Inhibitors for Treating Cancer Players: Market Share by Revenue in Checkpoint Inhibitors for Treating Cancer in 2025
Figure 20. Checkpoint Inhibitors for Treating Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 21. Global Checkpoint Inhibitors for Treating Cancer Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 22. North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2021–2032)
Figure 23. North America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2021–2032)
Figure 24. U.S. Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Canada Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2021–2032)
Figure 27. Europe Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2021–2032)
Figure 28. Germany Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. France Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. U.K. Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Italy Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Russia Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region (2021–2032)
Figure 34. Asia Pacific Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region (2021–2032)
Figure 35. China Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Japan Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. South Korea Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. India Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Australia Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. China Taiwan Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Indonesia Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Thailand Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Malaysia Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Latin America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2021–2032)
Figure 45. Latin America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2021–2032)
Figure 46. Mexico Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Brazil Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Argentina Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2021–2032)
Figure 50. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2021–2032)
Figure 51. Turkey Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. UAE Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Global Sales Market Share of Checkpoint Inhibitors for Treating Cancer by Type (2021–2032)
Figure 55. Global Revenue Market Share of Checkpoint Inhibitors for Treating Cancer by Type (2021–2032)
Figure 56. Global Checkpoint Inhibitors for Treating Cancer Price (USD/Unit) by Type (2021–2032)
Figure 57. Global Sales Market Share of Checkpoint Inhibitors for Treating Cancer by Application (2021–2032)
Figure 58. Global Revenue Market Share of Checkpoint Inhibitors for Treating Cancer by Application (2021–2032)
Figure 59. Global Checkpoint Inhibitors for Treating Cancer Price (USD/Unit) by Application (2021–2032)
Figure 60. Checkpoint Inhibitors for Treating Cancer Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
